TY - JOUR T1 - Removal of the race coefficient and adjustment to individual BSA provide the most accurate estimation for GFR in Black adolescents JF - medRxiv DO - 10.1101/2021.07.30.21261371 SP - 2021.07.30.21261371 AU - D Bielopolski AU - O Bentur AU - N Singh AU - R Vaughan AU - DM Charytan AU - RG Kost AU - JN Tobin Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/05/2021.07.30.21261371.abstract N2 - Introduction Obesity is more prevalent among minorities, increasing the risk for cardio-renal morbidity. We explored interactions between race, body mass index (BMI), and the risk of hyperfiltration associated with Obesity Related Glomerulopathy (ORG).Methods We created a cohort of women and girls ages 12-21 from the New York Metropolitan area using electronic health records. Glomerular filtration rate (GFR) was estimated in three ways: I) using the standard age recommended formulae, II) eGFRr – without a race-specific coefficient, and III) Absolute eGFRr – combing removal of the race coefficient and adjusting to individual body surface area. Multivariate logistic regression was used to analyze the relative contribution of risk factors for ORG associated hyperfiltration, defined by a threshold of ≥135ml/min/1.73m2. Bland Altman analysis and Pearson’s coefficient assessed the correlation of each formula with creatinine clearance (CrCl).Results 7315 Black and 15,102 non-Black women and girls had simultaneous evaluation of kidney function and body measures. CrCl was available in 207 non-Black and 107 Black individuals as an internal validation. Simultaneous removal of the race coefficient and adjustment to individual BSA estimated GFR most accurately compared to CrCl, across BMI groups and between races. Hyperfiltration was more frequent in obese Black compared to non-Black individuals when using standard eGFR (20% vs. 6.5% respectively) but had a lower frequency after eliminating the race-specific coefficient (4.5% vs. 6.5%). Black race was independently associated with a higher risk of hyperfiltration with standard eGFR calculations (OR=3.43, 95% CI 2.95-3.99) and with lower risk when estimated by eGFRr (OR=0.56, 95% CI 0.45-0.70). Simultaneous removal of the race coefficient from GFR calculation and adjustment to individual BSA attenuated the difference in risk between races (OR=0.8, 95% CI 0.68-0.94). The combined correction agreed well with creatinine clearance (Pearson’s correlation coefficient r=0.64, 0.52 and 0.52 for absolute eGFRr, eGFR and eGFRr respectively.Conclusions Removal of the race coefficient from GFR estimating equations obscures obesity associated hyperfiltration among Black adolescents. This correction should be accompanied by adjustment to individual BSA to improve estimation of GFR to avoid misclassification of obesity related hyperfiltration.Competing Interest StatementJonathan N. Tobin: NIH-NCI: Payments or Remuneration, Bio-Ascend LLC/Regional Cancer Care Associates: Payments or Remuneration, Reimbursed or Sponsored, Travel, AstraZeneca: Board of Directors Compensation, Payments or Remuneration, Reimbursed or Sponsored Travel. Clinical Directors Network, Inc. (CDN): Board of Directors Compensation, Payments or Remuneration, Reimbursed or Sponsored Travel. David M Charytan personal fees or fees paid by Janssen Pharmaceuticals to the Baim Institute. Consulting fees from Amgen, Eli Lilly, Fresenius, Gilead, Medtronic/Covidien, Merck, Novo Nordisk, Zoll, AstraZeneca, Merck, PLC Medical and Allena Pharmaceuticals. Research support from Medtronic and Amgen. All other authors have nothing to disclose. Funding StatementThis project was supported by: (1) The Sackler Center for Biomedicine and Nutrition Research at The Rockefeller University; (2) The Sackler Institute for Nutrition Science at The New York Academy of Sciences; (3) N2: Building a Network of Safety-Net PBRNs (AHRQ 1-P30-HS-021667); (4) The National Center for Advancing Translational Sciences grants to the Rockefeller University Center for Clinical and Translational Science, #UL1TR001866 and UL1 TR000043. (5) Patient-Centered Outcomes Research Institute (PCORI); contract number CDRN-1306-03961. (6) The Rockefeller University Clinical Scholar Endowment Fund. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Rockefeller University IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData have been provided by the INSIGHT Clinical Research Network and can be made available upon request. The INSIGHT Governance Board will review each request. BSAbody surface areaORGObesity Related GlomerulopathyGFRGlomerular filtration rateCrClCreatinine clearance ER -